Article
Source: Campus Sanofi

T1DM - Meta-Analysis

Author : Sanofi

Editorial Team

All relevant safety information about adverse reactions, precautions, and relevant contraindications can be found on the product page HERE.

T1-Meta Analysis

Download this clinical summary to read about the benefits of Toujeo® Insulin Glargine 300U/ml in this post-hoc meta-analysis of three Edition 6 month, phase III, randomised trials. The study aimed to explore the risk of hypoglycaemia with Toujeo^® vs insulin glargine 100U/mL in a broad pool of people with T1DM including children over the age of 6.

Download

See more from science

Toujeo

Toujeo^® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.

More about toujeo

Patient Materials

Find resources and support for your patients who have been prescribed Toujeo^®. This section will help you to help your patients understand the basis of living and staying well with diabetes and how to have a a positive start and experience with Toujeo^®.

Access patient materials